Up to 70% of patients with breast cancer are estrogen receptor positive (ER+) and can benefit from anti-estrogen therapy, Tamoxifen being most commonly prescribed for ER+ premenopausal breast cancer in order to prevent cancer relapse or metastases [1]. This evidence concerns the gene ESR1 and breast cancer.